FOXM1 and acute lymphoblastic leukemia: Thus, the treatment results of patient-derived pre- B ALL samples with the ARF26–44 peptide (Fig. 6) confirmed our findings from the genetic deletion experiments in the ALL mouse model (Fig. 5) and demonstrate that peptide-based inhibition/degradation of FOXM1 protein induces selective toxicity in B-cell lineage ALL cells.